GSK (NYSE:GSK) Trading Up 6.9% – Still a Buy?

Shares of GSK PLC Sponsored ADR (NYSE:GSK) were up 6.9% during mid-day trading on Tuesday . The stock traded as high as $55.62 and last traded at $55.5750. Approximately 1,685,655 shares traded hands during trading, a decline of 64% from the average daily volume of 4,652,362 shares. The stock had previously closed at $51.98.

More GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Second-quarter results beat expectations. Adjusted earnings were $1.36 per share, above the $1.27 consensus and up from $1.23 a year earlier. Revenue rose roughly 5% to £8.41 billion, exceeding forecasts, with vaccines helping drive the performance. GSK Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: GSK raised its FY 2026 adjusted EPS outlook to $4.90-$5.00, above the $4.79 analyst consensus. The improved profit outlook supports investor confidence in the company’s earnings momentum. GSK Hits Three-Month High as Vaccines Help Earnings Top Forecasts
• Positive Sentiment: A new cost-saving plan targets $2.52 billion in annual savings by 2029. Management intends to redirect resources toward faster development of medicines and its longer-term 2031 sales objectives. GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline
• Positive Sentiment: Pipeline news added support: partner Hansoh Pharmaceutical’s experimental cancer drug Ris-Rez met the primary goal in a late-stage bone-cancer trial, strengthening the potential value of GSK’s oncology collaboration. GSK, Hansoh’s Cancer Drug Meets Main Goal of Bone Cancer Trial
• Neutral Sentiment: GSK plans to invest £400 million in Britain over three years, including a new Cambridge R&D center. The investment may improve innovation, although it is also restructuring its research footprint. GSK to Invest £400 Million in Britain
• Negative Sentiment: FY 2026 revenue guidance of approximately $44.8 billion is below the $45.7 billion consensus. Additionally, reported EPS was $0.67, below consensus, although adjusted results were stronger; the discrepancy could create uncertainty around earnings quality.
• Negative Sentiment: Closing the Stevenage R&D hub and relocating operations to Cambridge will affect about 1,800 employees, creating execution, restructuring and near-term cost risks.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Wall Street Zen upgraded GSK from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of GSK in a research report on Tuesday, June 9th. HSBC upgraded GSK from a “reduce” rating to a “hold” rating in a research note on Monday, July 6th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of GSK in a research report on Thursday, July 9th. Finally, Jefferies Financial Group raised shares of GSK to a “strong-buy” rating in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, GSK has a consensus rating of “Hold” and a consensus target price of $53.00.

GSK Stock Performance

The company has a current ratio of 0.79, a quick ratio of 0.52 and a debt-to-equity ratio of 0.80. The company has a market cap of $108.73 billion, a PE ratio of 13.97, a P/E/G ratio of 3.27 and a beta of 0.35. The firm’s 50-day simple moving average is $51.62 and its two-hundred day simple moving average is $53.43.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, July 9th. Stockholders of record on Friday, May 15th were issued a dividend of $0.44 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $1.76 dividend on an annualized basis and a dividend yield of 3.3%. GSK’s payout ratio is 46.49%.

Hedge Funds Weigh In On GSK

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First Horizon Corp lifted its position in GSK by 78.7% during the 4th quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company’s stock worth $26,000 after acquiring an additional 236 shares during the period. Elyxium Wealth LLC purchased a new position in shares of GSK in the fourth quarter worth about $30,000. Triumph Capital Management acquired a new stake in shares of GSK during the third quarter worth about $40,000. Coston McIsaac & Partners boosted its position in GSK by 17.3% in the fourth quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company’s stock valued at $68,000 after buying an additional 206 shares during the last quarter. Finally, Bogart Wealth LLC increased its holdings in GSK by 15.3% in the 1st quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock worth $83,000 after buying an additional 200 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.